Endothelin receptor antagonism in patients with chronic heart failure.

[1]  D. Webb,et al.  Venous endothelin receptor function in patients with chronic heart failure. , 2000, Clinical science.

[2]  M. Böhm,et al.  Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. , 1999, Circulation.

[3]  D. Webb,et al.  Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. , 1999, Hypertension.

[4]  A. Davenport,et al.  Increased response to big endothelin‐1 in atherosclerotic human coronary artery: functional evidence for up‐regulation of endothelin‐converting enzyme activity in disease , 1998, British journal of pharmacology.

[5]  D. Webb,et al.  Nitric Oxide Synthesis and by Endothelin-B Receptor Blockade Mediated Vasodilatation Is Attenuated by Inhibition of − Endothelin-A Receptor Antagonist , 1998 .

[6]  J. McMurray,et al.  EndothelinBreceptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction , 1998 .

[7]  P. Vallance,et al.  Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. , 2003, British journal of clinical pharmacology.

[8]  D. Fukai,et al.  Comparison of the effects of selective endothelin ETA and ETB receptor antagonists in congestive heart failure. , 1997, Journal of the American College of Cardiology.

[9]  F. Lallemand,et al.  Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. , 1997, Circulation.

[10]  J. Kastrup,et al.  Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. , 1996, Cardiovascular research.

[11]  Y. Sugishita,et al.  Inhibition of myocardial endothelin pathway improves long-term survival in heart failure , 1996, Nature.

[12]  D. Webb,et al.  Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. , 1996, Circulation.

[13]  J. McMurray,et al.  Endothelin in chronic heart failure: current position and future prospects. , 1996, Cardiovascular research.

[14]  Y. Sugishita,et al.  Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. , 1996, Circulation.

[15]  G. Maurer,et al.  Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. , 1996, Journal of the American College of Cardiology.

[16]  A. Lerman,et al.  Enhanced Coronary Vasoconstriction to Endothelin-BReceptor Activation in Experimental Congestive Heart Failure , 1996 .

[17]  P. Hunziker,et al.  Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure , 1995, The Lancet.

[18]  D. Webb,et al.  Phosphoramidon inhibition of the in vivo conversion of big endothelin‐1 to endothelin‐1 in the human forearm , 1995, British journal of pharmacology.

[19]  D. Webb,et al.  Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. , 1995, Circulation.

[20]  P Vallance,et al.  Measuring forearm blood flow and interpreting the responses to drugs and mediators. , 1995, Hypertension.

[21]  G. Ahlborg,et al.  Metabolism of Big endothelin-1 (1–38) and (22–38) in the human circulation in relation to production of endothelin-1 (1–21) , 1995, Regulatory Peptides.

[22]  D. Webb,et al.  Measurement of C‐Terminal Fragment of Big Endothelin‐1: A Novel Method for Assessing the Generation of Endothelin‐1 in Humans , 1995, Journal of cardiovascular pharmacology.

[23]  D. Guédin,et al.  Why are circulating concentrations of endothelin-1 so low? , 1994, Cardiovascular research.

[24]  D. Webb,et al.  Contribution of endogenous generation of endothelin-1 to basal vascular tone , 1994, The Lancet.

[25]  M. Yanagisawa,et al.  ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1 , 1994, Cell.

[26]  T. Nagase,et al.  Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  W. Edwards,et al.  Endothelin in human congestive heart failure. , 1994, Circulation.

[28]  L. V. von Segesser,et al.  Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. , 1994, Circulation.

[29]  T. Fukami,et al.  Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. , 1992, Life sciences.

[30]  S. Nakanishi,et al.  Cloning and expression of a cDNA encoding an endothelin receptor , 1990, Nature.

[31]  T. Sakurai,et al.  Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor , 1990, Nature.

[32]  J. Vane,et al.  Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[33]  B. Robinson,et al.  Comparison of effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man. , 1978, British journal of clinical pharmacology.